Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
EQS-News

Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa 30.10.2026, 11:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Cambrex / Key word(s): Expansion
Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa

30.10.2026 / 11:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


EAST RUTHERFORD, N.J., Oct. 30, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today marked the groundbreaking of its $120 million expansion at its Charles City, Iowa facility.

CHARLES CITY, October 29, 2026  Cambrex Breaks Ground on $120 Million Expansion  From left to right: Joe Nettleton, VP Operations and Site Leader, Cambrex Charles City; Timothy Fox, CEO, Charles City Area Development Corporation; Senator Chuck Grassley, United States Senate; Lieutenant Governor Chris Cournoyer, State of Iowa; John Andrews, VP Operations, Cambrex; Claudio Russolo, COO and incoming CEO, Cambrex.

The expansion will add 160,000 liters of manufacturing capacity, increasing the site's total capacity by approximately 25% to nearly one million liters, supporting the development and commercial manufacturing of small molecule active pharmaceutical ingredients (APIs) and synthetic peptides. The project is anticipated to be completed in the fourth quarter of 2028.

Cambrex celebrated the start of construction with a groundbreaking ceremony on October 29, bringing together company leaders, employees, state and local officials and members of the Charles City community. The milestone comes as the Charles City site celebrates its 100th anniversary, marking a century of operations at the facility.

"This groundbreaking marks an important milestone in our continued investment in U.S. manufacturing and in the Charles City site," said Claudio Russolo, Chief Operating Officer and incoming Chief Executive Officer, Cambrex. "As the site celebrates its 100th anniversary, this expansion reflects both its long history and its continued importance to our future. By expanding commercial-scale capacity for both small molecule and peptide manufacturing, we are strengthening our ability to support customers as their programs advance from development through commercialization."

The Charles City facility provides development and manufacturing services for small molecule APIs, synthetic peptides and pharmaceutical intermediates, supporting projects from clinical development through commercial-scale production. The expansion builds on the site's existing infrastructure and technical expertise while providing additional capacity to meet customer demand.

About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.

With over 45 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs.

Cambrex Logo

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cambrex-breaks-ground-on-120-million-expansion-in-charles-city-iowa-302924343.html

rt.gif?NewsItemId=EN85144&Transmission_Id=202610300600PR_NEWS_EURO_ND__EN85144&DateId=20261030


30.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2425592  30.10.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 23:21 Uhr • Artikel • dpa-AFX

Gestern 23:17 Uhr • Artikel • dpa-AFX

Gestern 23:06 Uhr • Artikel • dpa

Gestern 23:03 Uhr • Artikel • dpa-AFX

Gestern 22:45 Uhr • Artikel • dpa-AFX

Gestern 22:41 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer